Herantis Pharma Plc. Employee Directory
Biotechnology ResearchCentral Finland, Finland11-50 Employees
Herantis Pharma Plc is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease. Its lead candidate, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor with the practicality of subcutaneous administration. In a Phase 1b trial, HER-096 was generally safe and well tolerated in people with Parkinson's disease, and the company plans to advance into a Phase 2 study in 2026 to evaluate efficacy and safety in early-stage patients. Based in Central Finland, the company operates in the biotechnology research sector and targets Parkinson's disease by pursuing therapies intended to slow disease progression. A recent development is the appointment of CTC Clinical Trial Consultants AB as the clinical CRO to support the Phase 2a trial.
1-888-653-2347 
support@leadiq.com 
